Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

Abstract Background Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients with moderate-to-severe atopic dermatitis (AD). We report the sustained impact of lebrikizumab monotherapy, over 52 weeks a...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Gil Yosipovitch, Peter Lio, Franz J. Legat, Raj Chovatiya, Mette Deleuran, Evangeline Pierce, Marta Casillas, Yuxin Ding, Fan E. Yang, Laia Bardolet, Sonja Ständer
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2024-07-01
Serija:	Dermatology and Therapy
Teme:	Atopic dermatitis Itch Lebrikizumab Sleep POEM
Online dostop:	https://doi.org/10.1007/s13555-024-01225-w
Oznake:	Označite Brez oznak, prvi označite!